Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Levi Strauss & Co. (LEVI) Price & Performance

Biogen IncTrade
Levi Strauss & Co.Trade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Levi Strauss & Co. — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Levi Strauss & Co. trades at $22.73 (market cap $8.75B). The key difference: Biogen Inc is far larger — about 3.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.81% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.

BIIBLEVI
Market Cap
$30.13B$8.75B
Sector
HealthConsumer Cyclical
52-Week High
$216.63$25.53
52-Week Low
$128.93$17.92
Enterprise Value
$37.20B$10.07B
Dividend Yield
2.81%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Levi Strauss & Co.

Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver

Read more on LEVI